1. Home
  2. IRD vs IGC Comparison

IRD vs IGC Comparison

Compare IRD & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IRD
  • IGC
  • Stock Information
  • Founded
  • IRD 2018
  • IGC 2005
  • Country
  • IRD United States
  • IGC United States
  • Employees
  • IRD N/A
  • IGC N/A
  • Industry
  • IRD
  • IGC Biotechnology: Pharmaceutical Preparations
  • Sector
  • IRD
  • IGC Health Care
  • Exchange
  • IRD NYSE
  • IGC Nasdaq
  • Market Cap
  • IRD 36.0M
  • IGC 29.4M
  • IPO Year
  • IRD N/A
  • IGC N/A
  • Fundamental
  • Price
  • IRD $1.14
  • IGC $0.31
  • Analyst Decision
  • IRD Strong Buy
  • IGC Strong Buy
  • Analyst Count
  • IRD 1
  • IGC 2
  • Target Price
  • IRD $8.00
  • IGC $3.75
  • AVG Volume (30 Days)
  • IRD 141.3K
  • IGC 359.1K
  • Earning Date
  • IRD 02-19-2025
  • IGC 02-18-2025
  • Dividend Yield
  • IRD N/A
  • IGC N/A
  • EPS Growth
  • IRD N/A
  • IGC N/A
  • EPS
  • IRD N/A
  • IGC N/A
  • Revenue
  • IRD $8,381,000.00
  • IGC $1,183,000.00
  • Revenue This Year
  • IRD N/A
  • IGC N/A
  • Revenue Next Year
  • IRD $29.37
  • IGC $13.38
  • P/E Ratio
  • IRD N/A
  • IGC N/A
  • Revenue Growth
  • IRD N/A
  • IGC N/A
  • 52 Week Low
  • IRD $0.81
  • IGC $0.27
  • 52 Week High
  • IRD $2.71
  • IGC $0.91
  • Technical
  • Relative Strength Index (RSI)
  • IRD N/A
  • IGC 38.84
  • Support Level
  • IRD N/A
  • IGC $0.30
  • Resistance Level
  • IRD N/A
  • IGC $0.33
  • Average True Range (ATR)
  • IRD 0.00
  • IGC 0.01
  • MACD
  • IRD 0.00
  • IGC -0.00
  • Stochastic Oscillator
  • IRD 0.00
  • IGC 16.00

About IRD OPUS GENETICS INC

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.

About IGC IGC Pharma Inc.

IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.

Share on Social Networks: